Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from HUTCHMED (China) ( (HK:0013) ).
HUTCHMED reported a significant increase in net income to $455 million for the first half of 2025, largely due to a $416.3 million gain from the partial disposal of a non-core joint venture. The company achieved notable progress in its clinical pipeline, with the approval of ORPATHYS® for a new lung cancer indication in China, and positive trial results for various drug candidates. These developments are expected to enhance HUTCHMED’s market positioning and provide new partnership opportunities, as the company continues to focus on sustainable growth and innovation in the biopharmaceutical sector.
More about HUTCHMED (China)
HUTCHMED (China) Limited operates in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company is known for its innovative drug pipeline and collaborations with multinational pharmaceutical companies, aiming to address unmet medical needs globally.
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.